Insider · CIK 0001785987

Larson Yi

Reports to the SEC for 4 companies · SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001785987

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	OLMAOlema Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+29.5K sh	—	—	29,500
2025-06-11	OLMAOlema Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+24.2K sh	—	—	24,150
2024-06-14	OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+23K sh	—	—	23,000
2024-02-26	RayzeBio, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−14.3K sh	—	—	0
2024-02-26	RayzeBio, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−40.8K sh	—	—	0
2024-02-26	RayzeBio, Inc.Employee Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−59.4K sh	—	—	0
2023-06-16	OLMAOlema Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+21.5K sh	—	—	21,520
2023-03-29	LIANYLianBioA Award	Chief Financial Officer	AAward	+326K sh	—	—	325,901
2023-01-20	LIANYLianBio · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+464K sh	—	—	464,099
2022-06-17	OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.5K sh	—	—	21,520
2022-06-16	OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.5K sh	—	—	21,520
2021-12-01	LIANYLianBio · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+5,996 sh	—	—	1,202,841
2021-10-31	LIANYLianBio · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+230K sh	—	—	1,196,845
2021-06-09	OLMAOlema Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+21.5K sh	—	—	21,520
2021-04-05	OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.5K sh	—	—	21,520
2021-04-05	OLMAOlema Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,773 sh	—	—	3,773
2021-02-08	Turning Point Therapeutics, Inc.Stock Option (right to buy)A Award	EVP & Chief Financial Officer	AAward	+20.8K sh	—	—	20,775
2021-02-08	Turning Point Therapeutics, Inc.A Award	EVP & Chief Financial Officer	AAward	+4,617 sh	—	—	7,321
2021-02-02	Turning Point Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−14.3K sh	—	—	282,397
2021-02-02	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−400 sh	$128.41	−$51.4K	15,602
2021-02-02	Turning Point Therapeutics, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+14.3K sh	$54.03	+$773K	17,002
2021-02-02	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−1,000 sh	$127.58	−$128K	16,002
2021-02-02	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−1,057 sh	$131.73	−$139K	2,704
2021-02-02	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−7,267 sh	$130.58	−$949K	3,761
2021-02-02	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−4,574 sh	$129.80	−$594K	11,028
2021-02-01	Turning Point Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	−15.7K sh	—	—	296,695
2021-02-01	Turning Point Therapeutics, Inc.M Exercise/Conversion	EVP & Chief Financial Officer	MExercise/Conversion	+15.7K sh	$54.03	+$848K	18,406
2021-02-01	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−4,783 sh	$122.94	−$588K	13,623
2021-02-01	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−8,576 sh	$123.70	−$1.06M	5,047
2021-02-01	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−2,143 sh	$124.60	−$267K	2,904
2021-02-01	Turning Point Therapeutics, Inc.S Sale	EVP & Chief Financial Officer	SSale	−200 sh	$126.07	−$25.2K	2,704
2020-01-06	Turning Point Therapeutics, Inc.Stock Option (right to buy)A Award	EVP & Chief Financial Officer	AAward	+33K sh	—	—	33,000
2019-09-10	Turning Point Therapeutics, Inc.P Purchase	EVP & Chief Financial Officer	PPurchase	+2,222 sh	$45.00	+$100K	2,222
2019-08-26	Turning Point Therapeutics, Inc.Stock Option (right to buy)A Award	EVP & Chief Financial Officer	AAward	+312K sh	—	—	312,397

Recent filings

Accepted (ET)
Jun 234
Larson Yi0001785987-26-000002
SEC(opens sec.gov)
Jun 134
Larson Yi0001415889-25-017240
SEC(opens sec.gov)
Jun 184
Larson Yi0001415889-24-017446
SEC(opens sec.gov)
Feb 274
Larson Yi0001415889-24-005516
SEC(opens sec.gov)
Jun 214
Larson Yi0001415889-23-010106
SEC(opens sec.gov)
Mar 314
Larson Yi0001831283-23-000051
SEC(opens sec.gov)
Jan 244
Larson Yi0001831283-23-000018
SEC(opens sec.gov)
Jun 274/A
Larson Yi0001415889-22-006965
SEC(opens sec.gov)
Jun 174
Larson Yi0001415889-22-006787
SEC(opens sec.gov)
Dec 34
Larson Yi0000899243-21-046751
SEC(opens sec.gov)
Nov 14
Larson Yi0000899243-21-042213
SEC(opens sec.gov)
Jun 104
Larson Yi0001415889-21-002924
SEC(opens sec.gov)
Apr 64
Larson Yi0001415889-21-001923
SEC(opens sec.gov)
Feb 104
Larson Yi0001209191-21-009370
SEC(opens sec.gov)
Feb 24
Larson Yi0001209191-21-007037
SEC(opens sec.gov)

Companies

Address

C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN ST

SAN FRANCISCO, CA, 94103